New research shows asthma drug's effectiveness over usual care alone

September 13, 2017 by Amy Mcsweeny
Credit: University of Plymouth

A new study co-authored by the University of Plymouth and published in The Lancet shows how an asthma drug was more effective at improving a patient's asthma control compared with their usual care.

The study was developed by pharmaceutical company GlaxoSmithKline (GSK), and showed that a once-daily inhalation of a powder, made up of drugs fluticasone furoate and 25mg Vilanterol (FF/VI), was noticeably more effective at improving scores in a test of , using a validated tool – the Asthma Control Test (ACT), than taking regular maintenance inhaler therapy alone.

Regular maintenance inhaler therapy is defined as taking (ICS) on their own, or in combination with a long-acting beta-agonist (LABA).

Commercially known as Relvar Ellipta, the was given to 2,114 of 4,233 for the study, with results monitored at 12, 24, 40 and 52 weeks.

And at 24 weeks, a significantly higher percentage of patients with symptomatic and initiated on treatment with FF/VI achieved better control of their asthma (71%), compared with patients continuing usual care treatment (56%), (odds ratio 2.00, 95% CI 1.70, 2.34; p<0.001). Statistically significant findings were also seen at 12, 40 and 52 weeks.

The ACT is used globally in asthma management and referenced in treatment guidelines to assess asthma control, and takes into consideration aspects such as how often patients use an intervention inhaler, and whether they have any time off work with asthma symptoms.

It is self-administered utilising five questions to assess asthma control during the past four weeks on a five-point categorical scale (1 to 5). By answering all five questions, a patient with asthma can obtain a score that may range between five and 25, with higher scores indicating better control.

The study, known as the Salford Lung Study, was led by the University of Manchester and took a novel approach to traditional randomised control trials. It included 4,233 patients from in and around Salford, and the only people excluded from the study were those who had reported life-threatening asthma recently, had a history of COPD or had a concomitant life-threatening disease. In this case, their care was continued as normal.

Dr Rupert Jones, Senior Clinical Research Fellow in Clinical Trials and Health Research at Plymouth University Peninsula Schools of Medicine and Dentistry, explained why the findings were so significant:

"As the study was carried out on a group of people in the general public, rather than considering any strict exclusion criteria, we can be confident it is translatable to the general public too," he said.

"Practices and pharmacists local to Salford were involved, and the study showed that the people taking the medication has twice the odds of achieving asthma as those on usual care. The Salford Lung Study was designed in collaboration with National Institute for Health and Care Excellence, and not only the findings but the way the methodologies of the research could be really influential on future work."

This is the second Salford Lung study to report, with the first publishing findings on COPD. It will add to the existing data set from double blind randomised clinical trials for the medicine which, while critical to establishing the safety and efficacy of a medicine, are conducted in a highly controlled environment and enrol a more highly selected patient population than would be expected in everyday clinical care.

The full study is titled "Effectiveness of Fluticasone Furoate / Vilanterol in Asthma in clinical practice."

Explore further: Once-daily triple-Tx improves lung function, HRQoL in COPD

More information: Ashley Woodcock et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial, The Lancet (2017). DOI: 10.1016/S0140-6736(17)32397-8

Related Stories

Once-daily triple-Tx improves lung function, HRQoL in COPD

August 22, 2017
(HealthDay)—For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled corticosteroid (ICS)/long-acting ...

Many students reluctant to use asthma inhalers at school

April 22, 2017
(HealthDay)—The thought of having to pull out an inhaler in the middle of school might stop some kids with asthma from breathing better, a study of British schoolchildren suggests.

Asthmatic schoolchildren are 'uncomfortable' using their inhalers

March 29, 2017
Poor asthma control and knowledge are common in children with doctor-diagnosed asthma, according to research by Queen Mary University of London (QMUL).

Inhaled steroids may increase pneumonia risk in people with asthma

April 20, 2017
Use of inhaled corticosteroids was linked with an increased risk of pneumonia in a study of individuals with asthma.

Study shows combination drug therapy for asthma patients is safe

August 31, 2016
A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective.

Salmeterol + fluticasone deemed safe for childhood asthma

September 2, 2016
(HealthDay)—Children using a combination long-acting beta agonist/steroid inhaler do not have any greater risk of harm than children using a steroid inhaler alone, according to a study published in the Sept. 1 issue of ...

Recommended for you

Gene immunotherapy protects against multiple sclerosis in mice

September 21, 2017
A potent and long-lasting gene immunotherapy approach prevents and reverses symptoms of multiple sclerosis in mice, according to a study published September 21st in the journal Molecular Therapy. Multiple sclerosis is an ...

New academic study reveals true extent of the link between hard water and eczema

September 21, 2017
Hard water damages our protective skin barrier and could contribute to the development of eczema, a new study has shown.

Exposure to pet and pest allergens during infancy linked to reduced asthma risk

September 19, 2017
Children exposed to high indoor levels of pet or pest allergens during infancy have a lower risk of developing asthma by 7 years of age, new research supported by the National Institutes of Health reveals. The findings, published ...

Cholesterol-like molecules switch off the engine in cancer-targeting 'Natural Killer' cells

September 18, 2017
Scientists have just discovered how the engine that powers cancer-killing cells functions. Crucially, their research also highlights how that engine is fuelled and that cholesterol-like molecules, called oxysterols, act as ...

MicroRNA helps cancer evade immune system

September 18, 2017
The immune system automatically destroys dysfunctional cells such as cancer cells, but cancerous tumors often survive nonetheless. A new study by Salk scientists shows one method by which fast-growing tumors evade anti-tumor ...

'Exciting' discovery on path to develop new type of vaccine to treat global viruses

September 15, 2017
Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.